Register or Sign in to Save this opportunity, or Send an Inquiry.
New Use for FDA Approved Drug-treatment of Microbial Infections with NTBC
Milwaukee Regional Technology Transfer Group United States flag United States
Abstract ID:
Dr. Graham Moran and collaborators have shown that 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) decreases pigment production in the bacterium B. cenocepacia and aids in phagolysosomal fusion in macrophages
Send an Inquiry
RE:
Participants
You
Technology

Dr. Graham Moran and collaborators have shown that 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) decreases pigment production in the bacterium B. cenocepacia and aids in phagolysosomal fusion in macrophages infected with this bacteria in vitro.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

This technology is part of an active and ongoing research program and is seeking partners for development of the final product.  It is available for developmental research support/licensing under either exclusive or non-exclusive terms.

FEATURED
Last Updated Oct 2014
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
UNIVERSITY

Opportunity Contact